|
1
|
Vogelzang NJ, Rusthoven JJ, Symanowski J,
Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S,
Manegold C, et al: Phase III study of pemetrexed in combination
with cisplatin versus cisplatin alone in patients with malignant
pleural mesothelioma. J Clin Oncol. 21:2636–2644. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhan T, Rindtorff N and Boutros M: Wnt
signaling in cancer. Oncogene. 36:1461–1473. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Uematsu K, Kanazawa S, You L, He B, Xu Z,
Li K, Peterlin BM, McCormick F and Jablons DM: Wnt pathway
activation in mesothelioma: Evidence of dishevelled overexpression
and transcriptional activity of β-catenin. Cancer Res.
63:4547–4551. 2003.PubMed/NCBI
|
|
4
|
Uematsu K, He B, You L, Xu Z, McCormick F
and Jablons DM: Activation of the Wnt pathway in non small cell
lung cancer: Evidence of dishevelled overexpression. Oncogene.
22:7218–7221. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
He B, You L, Uematsu K, Xu Z, Lee AY,
Matsangou M, McCormick F and Jablons DM: A monoclonal antibody
against Wnt-1 induces apoptosis in human cancer cells. Neoplasia.
6:7–14. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
You L, He B, Xu Z, Uematsu K, Mazieres J,
Fujii N, Mikami I, Reguart N, McIntosh JK, Kashani-Sabet M, et al:
An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant
melanoma cells and inhibits tumor growth. Cancer Res. 64:5385–5389.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fujii N, You L, Xu Z, Uematsu K, Shan J,
He B, Mikami I, Edmondson LR, Neale G, Zheng J, et al: An
antagonist of dishevelled protein-protein interaction suppresses
β-catenin-dependent tumor cell growth. Cancer Res. 67:573–579.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
You L, He B, Uematsu K, Xu Z, Mazieres J,
Lee A, McCormick F and Jablons DM: Inhibition of Wnt-1 signaling
induces apoptosis in β-catenin-deficient mesothelioma cells. Cancer
Res. 64:3474–3478. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Stewart DJ: Wnt signaling pathway in
non-small cell lung cancer. J Natl Cancer Inst. 106:djt3562014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dazzi H, Hasleton PS, Thatcher N, Wilkes
S, Swindell R and Chatterjee AK: Malignant pleural mesothelioma and
epidermal growth factor receptor (EGF-R). Relationship of EGF-R
with histology and survival using fixed paraffin embedded tissue
and the F4, monoclonal antibody. Br J Cancer. 61:924–926. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Govindan R, Kratzke RA, Herndon JE II,
Niehans GA, Vollmer R, Watson D, Green MR and Kindler HL; Cancer
and Leukemia Group B (CALGB 30101), : Gefitinib in patients with
malignant mesothelioma: A phase II study by the cancer and leukemia
group B. Clin Cancer Res. 11:2300–2304. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Casás-Selves M, Kim J, Zhang Z, Helfrich
BA, Gao D, Porter CC, Scarborough HA, Bunn PA Jr, Chan DC, Tan AC
and DeGregori J: Tankyrase and the canonical Wnt pathway protect
lung cancer cells from EGFR inhibition. Cancer Res. 72:4154–4164.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fong JT, Jacobs RJ, Moravec DN, Uppada SB,
Botting GM, Nlend M and Puri N: Alternative signaling pathways as
potential therapeutic targets for overcoming EGFR and c-Met
inhibitor resistance in non-small cell lung cancer. PLoS One.
8:e783982013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Togashi Y, Hayashi H, Terashima M, de
Velasco MA, Sakai K, Fujita Y, Tomida S, Nakagawa K and Nishio K:
Inhibition of β-catenin enhances the anticancer effect of
irreversible EGFR-TKI in EGFR-mutated non-small-cell lung cancer
with a T790M mutation. J Thorac Oncol. 10:93–101. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang Y, Zhang X, Huang J and Dong Q: Wnt
signaling regulation of stem-like properties in human lung
adenocarcinoma cell lines. Med Oncol. 32:1572015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Uematsu K, Seki N, Seto T, Isoe C,
Tsukamoto H, Mikami I, You L, He B, Xu Z, Jablons DM and Eguchi K:
Targeting the wnt signaling pathway with dishevelled and cisplatin
synergistically suppresses mesothelioma cell growth. Anticancer
Res. 27:4239–4242. 2007.PubMed/NCBI
|
|
18
|
Jänne PA, Taffaro ML, Salgia R and Johnson
BE: Inhibition of epidermal growth factor receptor signaling in
malignant pleural mesothelioma. Cancer Res. 62:5242–5247.
2002.PubMed/NCBI
|
|
19
|
Nutt JE, O'Toole K, Gonzalez D and Lunec
J: Growth inhibition by tyrosine kinase inhibitors in mesothelioma
cell lines. Eur J Cancer. 45:1684–1691. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zheng H, Saito H, Masuda S, Yang X and
Takano Y: Phosphorylated GSK3beta-ser9 and EGFR are good prognostic
factors for lung carcinomas. Anticancer Res. 27:3561–3569.
2007.PubMed/NCBI
|
|
21
|
McCubrey JA, Rakus D, Gizak A, Steelman
LS, Abrams SL, Lertpiriyapong K, Fitzgerald TL, Yang LV, Montalto
G, Cervello M, et al: Effects of mutations in Wnt/β-catenin,
hedgehog, notch and PI3K pathways on GSK-3 activity-diverse effects
on cell growth, metabolism and cancer. Biochim Biophys Acta.
1863:2942–2976. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Paul I, Bhattacharya S, Chatterjee A and
Ghosh MK: Current understanding on EGFR and Wnt/β-catenin signaling
in glioma and their possible crosstalk. Genes Cancer. 4:427–446.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hu T and Li C: Convergence between
Wnt-β-catenin and EGFR signaling in cancer. Mol Cancer. 9:2362010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gao C and Chen YG: Dishevelled: The hub of
Wnt signaling. Cell Signal. 22:717–727. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhao H, Zhao Y, Jiang G, Zhang X, Zhang Y,
Dong Q, Luan L, Papavassiliou P and Wang E: Dishevelled-3 activates
p65 to upregulate p120-catenin transcription via a p38-dependent
pathway in non-small cell lung cancer. Mol Carcinog. 54:E112–E121.
2015. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang X, Yu X, Jiang G, Miao Y, Wang L,
Zhang Y, Liu Y, Fan C, Lin X, Dong Q, et al: Cytosolic TMEM88
promotes invasion and metastasis in lung cancer cells by binding
DVLs. Cancer Res. 75:4527–4537. 2015. View Article : Google Scholar : PubMed/NCBI
|
